Literature DB >> 11192715

Use of the rat pancreatic CA20948 cell line for the comparison of radiolabelled peptides for receptor-targeted scintigraphy and radionuclide therapy.

B F Bernard1, E Krenning, W A Breeman, T J Visser, W H Bakker, A Srinivasan, M de Jong.   

Abstract

We have evaluated the usefulness of the rat pancreatic CA20948 tumour as an in vitro cell culture model and as an in vivo model in Lewis rats comparing different radiolabelled peptides for receptor-targeted scintigraphy. In vitro the receptor-specific uptake and internalization of different radiolabelled analogues of somatostatin, bombesin, substance P and cholecystokinin were demonstrated. Analogues were selected based on high-affinity binding to their respective receptors. Their uptake and internalization in CA20948 cells were compared to these processes in AR42J cells, a well-known rat pancreatic tumour cell line used for peptide-receptor studies. Receptor-specific internalization, which was blocked by excess unlabelled peptide analogue, was found in both the CA20948 and AR42J cells for all the peptide analogues tested. This indicates specific receptor expression for all the different peptides, making these cells highly suitable for peptide studies. Internalization of the different peptides was as follows, in increasing order: [111In-DOTA0]CCK < [111In-DTPA0,Arg1]substance P < [111In-DTPA0]octreotide < [111In-DTPA0,Pro1,Tyr4]bombesin. Internalization appeared to be time and temperature dependent. In accordance with the in vitro experiments, receptor-specific uptake of all the peptide analogues was also found in vivo in the solid CA20948 tumour. The in vivo tumour uptake of [111n-DTPA0]octreotide was the highest amongst the peptides tested, the order of tumour uptake being [111In-DTPA0]octreotide >[111In-DTPA0,Pro1,Tyr4]bombesin >[111In-DTPA0,Arg1]substance P > [111In-DOTA0]CCK, which is different from the in vitro findings and points to either different receptor numbers on the tumour cells for the different peptide receptors in vitro and in vivo or to differences between the peptides with regard to metabolic stability. It can be concluded that the CA20948 tumour, both in cell culture and as a solid tumour in rats, is a very useful model for peptide receptor scintigraphy and radionuclide therapy studies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11192715     DOI: 10.1097/00006231-200011000-00015

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  12 in total

Review 1.  Bombesin receptor-mediated imaging and cytotoxicity: review and current status.

Authors:  Veronica Sancho; Alessia Di Florio; Terry W Moody; Robert T Jensen
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

2.  Long-term toxicity of [(177)Lu-DOTA (0),Tyr (3)]octreotate in rats.

Authors:  Edgar J Rolleman; Eric P Krenning; Bert F Bernard; Monique de Visser; Magda Bijster; Theo J Visser; Marcel Vermeij; Jan Lindemans; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-09-22       Impact factor: 9.236

3.  [(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tate.

Authors:  Theodosia Maina; Berthold A Nock; Paul Cordopatis; Bert F Bernard; Wout A P Breeman; Arthur van Gameren; Ria van den Berg; Jean-Claude Reubi; Eric P Krenning; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-28       Impact factor: 9.236

4.  Novel 111In-labelled bombesin analogues for molecular imaging of prostate tumours.

Authors:  M de Visser; H F Bernard; J L Erion; M A Schmidt; A Srinivasan; B Waser; J C Reubi; E P Krenning; M de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02-08       Impact factor: 9.236

5.  Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy.

Authors:  Stephen J Mather; Andrew J McKenzie; Jane K Sosabowski; Teresa M Morris; David Ellison; Susan A Watson
Journal:  J Nucl Med       Date:  2007-04       Impact factor: 10.057

6.  Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor.

Authors:  Nupur K Purohit; Rashmi G Shah; Samuel Adant; Michael Hoepfner; Girish M Shah; Jean-Mathieu Beauregard
Journal:  Oncotarget       Date:  2018-05-15

7.  Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotate in rats with CA20948 tumours.

Authors:  Marleen Melis; Magda Bijster; Monique de Visser; Mark W Konijnenberg; Jan de Swart; Edgar J Rolleman; Otto C Boerman; Eric P Krenning; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12       Impact factor: 9.236

8.  Peptide receptor radionuclide therapy (PRRT) with [(177)Lu-DOTA(0),Tyr(3)]octreotate in combination with RAD001 treatment: further investigations on tumor metastasis and response in the rat pancreatic CA20948 tumor model.

Authors:  Sander M Bison; Stefan E Pool; Stuart J Koelewijn; Linda M van der Graaf; Harald C Groen; Marleen Melis; Marion de Jong
Journal:  EJNMMI Res       Date:  2014-05-30       Impact factor: 3.138

9.  Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib.

Authors:  Julie Nonnekens; Melissa van Kranenburg; Cecile E M T Beerens; Mustafa Suker; Michael Doukas; Casper H J van Eijck; Marion de Jong; Dik C van Gent
Journal:  Theranostics       Date:  2016-07-18       Impact factor: 11.556

10.  Imaging DNA Damage Repair In Vivo After 177Lu-DOTATATE Therapy.

Authors:  Edward O'Neill; Veerle Kersemans; P Danny Allen; Samantha Y A Terry; Julia Baguña Torres; Michael Mosley; Sean Smart; Boon Quan Lee; Nadia Falzone; Katherine A Vallis; Mark W Konijnenberg; Marion de Jong; Julie Nonnekens; Bart Cornelissen
Journal:  J Nucl Med       Date:  2019-11-22       Impact factor: 11.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.